

**Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2022/2023 influenza season**

as of October 12, 2023

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
<b>Resistant (%)</b>	0	1 (1.2%)	1 (1.2%)	0	0	57 (100%)	9 (1.7%)	0	0	0	0	312 (100%)	0	0	0	0	0
<b>Number of viruses tested</b>	59	83	83	54	54	57	518	303	303	303	303	312	50	48	48	48	48
<b>Number of viruses reported</b>	165						3,411						84				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.